Dermatologists have warned that applying adult skincare products and alcohol-based creams on babies puts them at risk of skin ...

Cases of the autoimmune skin condition eczema appear to rise in areas most plagued by air pollution, new research shows.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Both body creams and lotions hydrate skin, but they have a few key differences. The main is consistency. Here’s how to tell ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...